Akari Therapeutics, Plc (AKTX)

NASDAQ: AKTX · USD

$9.15

+0.57 (+6.6%)· Recorded snapshot

Market cap	20.9M
Net income (ttm)	-31M
EPS (ttm)	-$23.9
Shares out	2.3M
Volume	42,179
Beta	1.44

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -31M
EPS (ttm): -$23.9
Market cap: 20.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-140.1

P25 n/aP50 n/aP75 n/a

ROIC-36.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AKTX indicators

Market & fundamental data

Available fields

171

Groups with data

Currency

USD

Showing 171 of 171 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001541157
Company name	Akari Therapeutics, Plc
Country	United States
Country code	US
CUSIP number	00972G405
Earnings date	2026-11-12
Earnings time	amc
Employees	6
Employees change	-3
Employees growth	-33.33%
Enterprise value	$13.9M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US00972G4055
Last 10-K release date	2026-03-30
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split date	2026-03-31
Last stock split type	Reverse
Market cap	$20.9M
Market cap category	Nano-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$9.15
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	AKTX
U.S. state	Florida
Website	https://www.akaritx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-261.63%
FCF / EV yield	-76.11%
FCF yield	-50.9%
P/B ratio	0.81x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-5.2M
ROA	-19.1%
ROA (5Y)	-72.8%
ROCE	-55.41%
ROE	-140.09%
ROE (5Y)	-449.26%
ROIC	-36.82%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-13.7M
EPS	$-23.94
FCF per share	$-4.71
Financing cash flow	$15.7M
Free cash flow	$-10.8M
Free cash flow minus SBC	$-12.9M
Income taxes	$-1.9M
Net borrowing	$1.4M
Net cash flow	$5M
Net income	$-31M
Operating cash flow minus SBC	$-12.9M
Operating income	$-13.7M
Stock-based compensation	$2.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$10.62
Debt / equity	0.04
Interest coverage	-13.89
Long-term assets	$30.3M
Long-term liabilities	$6.1M
Net cash (debt)	$7M
Net cash / market cap	33.12%
Net cash growth	501.46%
Net debt / equity	-0.38
Piotroski F-Score	2
Shareholders' equity	$18.6M
Tangible book value	$-11.7M
Tangible book value per share	$-6.69
Total assets	$38.6M
Total cash	$7.7M
Total debt	$693,000
Total liabilities	$20M
WACC	15.35%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$8.3M
Current liabilities	$13.9M
Current ratio	0.6
Net working capital	$-12.6M
Quick ratio	0.55
Working capital	$-5.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-128.91%
Dividend yield	0%
Shareholder yield	-128.91%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-99.88%
10Y return CAGR	-48.77%
10Y total return	-99.88%
150-day SMA	$8.98
1D price change	6.64%
1M price change	-6.2%
1M total return	-6.2%
1W price change	-1.51%
1W total return	-1.51%
1Y price change	-71.2%
1Y return CAGR	-71.23%
1Y total return	-71.2%
20-day SMA	$8.54
200-day SMA	$9.09
3M price change	8.16%
3M total return	8.16%
3Y price change	-93.65%
3Y return CAGR	-60.09%
3Y total return	-93.65%
50-day SMA	$9.27
50-day SMA vs 200-day SMA	50over200
52-week high	$33.60
52-week high date	2025-11-04
52-week low	$3.02
52-week low date	2026-05-12
5Y price change	-99.31%
5Y return CAGR	-63.05%
5Y total return	-99.31%
6M price change	63.39%
6M total return	63.39%
All-time high	$20,880.00
All-time high date	2015-09-28
All-time low	$3.02
All-time low date	2026-05-12
Average true range (ATR)	$1.05
Average volume	40.7K
Beta (1Y)	4.92
Beta (2Y)	1.56
Beta (5Y)	1.44
Change from 52-week high	-72.77%
Change from 52-week low	203.48%
Change from all-time high	-99.96%
Change from all-time low	203.48%
Change from open	0.44%
Day's gap	6.18%
Dollar volume	$385,938
High price	$9.18
Low price	$9.11
Monthly RSI	32.77
Open price	$9.11
Position in 52-week range	57.14%
Previous close	$8.58
Price vs 150-day SMA	1.86%
Price vs 20-day SMA	7.16%
Price vs 200-day SMA	0.68%
Price vs 50-day SMA	-1.32%
Relative volume	1.04
RSI	52.19
Sharpe ratio	0.36
Sharpe ratio (3Y)	0.09
Sharpe ratio (5Y)	-0.15
Sortino ratio	1.1
Sortino ratio (3Y)	0.27
Sortino ratio (5Y)	-0.25
Volume	42.2K
Weekly RSI	46.63
YTD price change	-20.85%
YTD total return	-20.85%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.7M
Float percentage	73.26%
Shares change (QoQ)	20.68%
Shares change (YoY)	128.91%
Shares held by insiders	26.3%
Shares held by institutions	185.54%
Shares outstanding	2.3M
Short % of shares	1.15%
Short ratio	0.2 days

Deeper analysis on AKTX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AKTX report

Is a complete AKTX research report available?

No complete published report is available for Akari Therapeutics, Plc (AKTX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Akari Therapeutics, Plc (AKTX)

Price

Financial snapshot

Fair-value bridge

Latest news · AKTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AKTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AKTX

Frequently asked questions